Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines

Elmire Hartmans, Matthijs D. Linssen, Claire Sikkens, Afra Levens, Max J. H. Witjes, Gooitzen M. van Dam, Wouter B. Nagengast*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
241 Downloads (Pure)

Abstract

Esophageal carcinoma (EC) is a global health problem, with disappointing 5-year survival rates of only 15-25%. Near-infrared targeted photodynamic therapy (NIR-tPDT) is a novel strategy in which cancer-targeted phototoxicity is able to selectively treat malignant cells. In this in vitro report we demonstrate the applicability of antibody-based NIR-tPDT in esophageal adenocarcinoma (EAC), using the phototoxic compounds cetuximab-IRDye700DX and trastuzumab-IRDye700DX, targeting respectively epidermal growth factor receptor 1 (EGFR) and 2 (HER2). Furthermore, we demonstrate that NIR-tPDT can be made more effective by tyrosine kinase inhibitor (TKI) induced growth receptor upregulation. Together, these results unveil a novel strategy for non-invasive EAC treatment, and by pretreatment-induced receptor upregulation its future clinical application may be optimized.

Original languageEnglish
Pages (from-to)29846-29856
Number of pages11
JournalOncotarget
Volume8
Issue number18
DOIs
Publication statusPublished - 13-Mar-2017

Keywords

  • targeted photodynamic therapy
  • esophageal cancer
  • epidermal growth factor receptor family (HER-family)
  • targeted treatment
  • TRASTUZUMAB-BASED PHOTOIMMUNOTHERAPY
  • HIGH-GRADE DYSPLASIA
  • BARRETTS-ESOPHAGUS
  • MONOCLONAL-ANTIBODIES
  • BREAST-CANCER
  • TUMORS
  • EGFR
  • HER2
  • EXPRESSION
  • TRANSDUCTION

Cite this